🇺🇸 Vincristine Liposomal in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 13

Most-reported reactions

1. Gastroduodenal Ulcer — 2 reports (15.38%)
2. Neoplasm Progression — 2 reports (15.38%)
3. Pulmonary Embolism — 2 reports (15.38%)
4. Blood Creatinine Increased — 1 report (7.69%)
5. Chest Discomfort — 1 report (7.69%)
6. Death — 1 report (7.69%)
7. Fatigue — 1 report (7.69%)
8. Febrile Neutropenia — 1 report (7.69%)
9. Fungaemia — 1 report (7.69%)
10. General Physical Health Deterioration — 1 report (7.69%)

Source database →

Frequently asked questions

Is Vincristine Liposomal approved in United States?

Vincristine Liposomal does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Vincristine Liposomal in United States?

University of Southern California is the originator. The local marketing authorisation holder may differ — check the official source linked above.